Provided by Tiger Trade Technology Pte. Ltd.

Global X Aging Population ETF

38.63
+0.19370.50%
Volume:4K
Turnover:163.12K
Market Cap:95.41M
PE:- -
High:38.83
Open:38.82
Low:38.56
Close:38.44
52wk High:39.48
52wk Low:32.44
Shares:2.47M
Float Shares:2.47M
Volume Ratio:0.53
T/O Rate:0.17%
Dividend:0.33
Dividend Rate:0.85%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Guizhou-Based Firm Earns National Recognition for Veterans Support Efforts

Deep News
·
17 mins ago

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Stock News
·
10 hours ago

Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
14 hours ago

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
16 hours ago

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live
·
17 hours ago

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
18 hours ago

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live
·
Yesterday

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

Dow Jones
·
Yesterday

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

TIPRANKS
·
Yesterday

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Reuters
·
Yesterday

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS
·
Yesterday

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS
·
Yesterday

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS
·
Yesterday

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS
·
Yesterday

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live
·
Yesterday

Apogee Therapeutics Shares Face NASDAQ Suspension as Company Moves to Delist After AbbVie Merger

Reuters
·
Yesterday

Aspen Sees Mounjaro Africa Sales Above $124 Million in 2027

Reuters
·
Yesterday

Abbvie Completes Acquisition of Apogee Therapeutics

THOMSON REUTERS
·
Yesterday

Abbvie - Reaffirms 2026 Q3 Adj Diluted EPS Guidance $3.84-$3.88

THOMSON REUTERS
·
Yesterday

AbbVie to Present at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Yesterday